Editas Medicine

Forecast & Rating13 analysts currently cover Editas Medicine, with about 53.8% giving a positive rating — meaning they expect the stock to rise. The average price target is $6.00, about 96.1% upside from the current price of $3.06. Price targets range from $1.00 to $15.00 — a wide spread, showing clear disagreement over just how much Editas Medicine can rise. Historically, about 20.0% of past price targets were eventually met, which adds credibility. For you, this means institutional views on Editas Medicine are split — bulls and bears coexist, so you'll need to weigh it against your own judgment. Data as of Aug 18, 2026; for reference only and not investment advice.